Uterine cervical cancer after liver transplantation: a case report

Concomitant external beam radiotherapy and chemotherapy followed by brachytherapy has been the primary treatment option for locally advanced cervical cancer. A patient with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB cervical cancer diagnosed after liver transplantation, who was not the candidate of chemotherapy due to her impaired liver and renal function, was treated with radiotherapy alone including three-dimensional conformal radiotherapy (3D-CRT) and brachytherapy. The diagnosis, treatment, and prognosis were reviewed in detail. No tumor progression or metastatic lesions and no severe complications were observed at 33-month follow-up.

Liver transplantation; Uterine cervical cancer; Three-dimensional conformal radiotherapy; Brachytherapy.

[1] Buell J.F., Gross T.G., Woodle E.S.: “Malignancy after transplantation”. Transplantation, 2005, 2, S254.

[2] Xiol X., Guardiola J., Menendez S., Lama C., Figueras J., Marcoval J., et al.: “Risk factors for development of de novo neoplasia after liver transplantation”. Liver Transpl., 2001, 11, 971.

[3] Baccarani U., Adani G.L., Serraino D., Lorenzin D., Gambato M., Buda A., et al.: “De novo tumors are a major cause of late mortality after orthotopic liver transplantation”. Transplant Proc., 2009, 4, 1303.

[4] Marques Medina E., Jimenez Romero C., Gomez de la Camara A., Rota Bernal A., Manrique Municio A., Moreno Gonzalez E.: “Malignancy after liver transplantation: cumulative risk for development”. Transplant Proc., 2009, 6, 2447.

[5] Penn I.: “Cancers in renal transplant recipients”. Adv. Ren. Replace Ther., 2000, 2, 147.

[6] Piselli P., Busnach G., Citterio F., Frigerio M., Arbustini E., Burra P., et al.: “Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4,767 recipients in Italy, 1970-2006”. Transplant Proc., 2009, 4, 1227.

[7] Shoji F., Yano T., Soejima Y., Taketomi A., Takeshita M., Sueishi K., et al.: “Multiple pulmonary mucosa-associated lymphoid tissue lymphomas after living donor liver transplantation”. Liver Transpl., 2009, 12, 1891.

[8] Small W. Jr., Mell L.K., Anderson P., Creutzberg C., De Los Santos J., Gaffney D., et al.: “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2008, 2, 428.

[9] Haagsma E.B., Hagens V.E., Schaapveld M., van den Berg A.P., de Vries E.G., Klompmaker I.J., et al.: “Increased cancer risk after liver transplantation: a population-based study”. J. Hepatol., 2001, 1, 84.

[10] Husted T.L., Buell J.F., Hanaway M.J., Trofe J., Beebe T., Gross T.,et al.: “De novo sarcomas in solid organ transplant recipients”. Transplant Proc., 2002, 5, 1786.

[11] Vallejo G.H., Romero C.J., de Vicente J.C.:”Incidence and risk factors for cancer after liver transplantation”. Crit. Rev. Oncol. Hematol., 2005, 1, 87.

[12] Tanaka Y., Asada H., Uchida H., Maruyama T., Kuji N., Sueoka K., et al.: “Case of iatrogenic dysmenorrhea in non-communicating rudimentary uterine horn and its laparoscopic resection”. J. Obstet. Gynaecol. Res., 2005, 3, 242.

[13] Nagarsheth N.P., Kalir T., Rahaman J.: “Post-transplant lymphoproliferative disorder of the cervix”. Gynecol. Oncol., 2005, 1, 271.

[14] Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al.: “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med., 2003, 6, 518.

[15] de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al.: “Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study”. Lancet Oncol., 2010, 11, 1048.

[16] Meyer T., Arndt R., Beckmann E.R., Padberg B., Christophers E., Stockfleth E.: “Distribution of HPV 53, HPV 73 and CP8304 in genital epithelial lesions with different grades of dysplasia”. Int. J. Gynecol. Cancer, 2001, 3, 198.

[17] Tahmasbi Rad M., Wallwiener M., Schemmer P., Schott S., Sohn C., Rom J., et al.:”Laparoscopically assisted vaginal hysterectomy in a patient with micro-invasive cervical cancer after two liver transplantations”. J. Obstet. Gynaecol. Can., 2012, 4, 363.

[18] Kim N.R., Lim S., Cho H.Y.: “Pediatric vulvar squamous cell carcinoma in a liver transplantation recipient: a case report”. J. Gynecol. Oncol., 2011, 3, 207.

[19] Jeong B.K., Choi D.H., Huh S.J., Park W., Bae D.S., Kim B.G.: “The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix”. Radiation Oncol J., 2011, 3, 191.

[20] Aberg F., Pukkala E., Hockerstedt K., Sankila R., Isoniemi H.: “Risk of malignant neoplasms after liver transplantation: a populationbased study”. Liver Transpl., 2008, 10, 1428.

[21] Roeske J.C., Lujan A., Rotmensch J., Waggoner S.E., Yamada D., Mundt A.J.: “Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies”. Int. J. Radiat. Oncol. Biol. Phys., 2000, 5, 1613.

[22] Ahamad A., D’Souza W., Salehpour M., Iyer R., Tucker S.L., Jhingran A., et al.:”Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 4, 1117.

[23] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration: “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials”. J. Clin. Oncol., 2008, 35, 5802.